close
MENU
General Business
4 mins to read

Covid-19 ‘vaccine enhancer’ startup adds mRNA version

CVC’s Robert Feldman says government should put more money in.

Kiwi startup Covid-19 Corporation (CVC) has partnered with an Australian biomanufacturer to develop an mRNA version of its Covid-19 vaccine enhancer.

CVC, formed in May 2020, is working on a proprietary T-cell-based vaccine enhancer designed to be given with existing Covid-19 vaccines to broaden

Want to read more? It's easy.

Choose your best value subscription option

Student

Exclusive offer for uni students studying at a New Zealand university (valued at $499).
Individual
Group membership
NBR Marketplace

Yearly Premium Online Subscription

NZ$499.00 / yearly

Monthly Premium Online Subscription

NZ$44.95 / monthly

Smartphone Only Subscription

NZ$24.95 / monthly

Premium Group Membership 10 Users

NZ$350+GST / monthly

$35 per user - Pay by monthly credit card debit

Premium Group Membership 20 Users

NZ$600+GST / monthly

$30 per user - Pay by monthly credit card debit

Premium Group Membership 50 Users

NZ$1250+GST / monthly

$25 per user - Pay by monthly credit card debit

Premium Group Membership 100 Users

NZ$1875+GST / monthly

$18.75 per user - Pay by monthly credit card debit

Yearly Premium Online Subscription + NBR Marketplace

NZ$499.00 / yearly

Already have an account? Login
Contact the Writer: nicola@nbr.co.nz
News tip? Question? Typo? Let us know: editor@nbr.co.nz
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.
Covid-19 ‘vaccine enhancer’ startup adds mRNA version
General Business,
88971
true